Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models

Esophageal carcinoma is the most rapidly increasing tumor in the United States and has a dismal 15% 5-year survival. Immunotherapy has been proposed to improve patient outcomes; however, no immunocompetent esophageal carcinoma model exists to date to test this approach. We developed two mouse models...

Descripción completa

Detalles Bibliográficos
Autores principales: Predina, J D, Judy, B, Aliperti, L A, Fridlender, Z G, Blouin, A, Kapoor, V, Laguna, B, Nakagawa, H, Rustgi, A K, Aguilar, L, Aguilar-Cordova, E, Albelda, S M, Singhal, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215998/
https://www.ncbi.nlm.nih.gov/pubmed/21869822
http://dx.doi.org/10.1038/cgt.2011.56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215998/
https://www.ncbi.nlm.nih.gov/pubmed/21869822
http://dx.doi.org/10.1038/cgt.2011.56

Ejemplares similares